PROOF 302 Trial Enrolling Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations Ohio State University-Led Trial to Study Infigratinib for Treatment of Patients with Advanced or Metastatic Solid Tumors with FGFR Genetic Alterations SAN...
The Christie NHS Foundation Trust and Innovative Trials, a clinical trial patient recruitment company, has announced a pioneering partnership to tackle the issue of patient diversity within clinical trials and help speed up research so that effective treatments come...
Netherlands Cancer Institute Intends to Sponsor and Conduct Phase 1/1b SHERPA Trial in Patients with Tumors Harboring RAS Mutations REDWOOD CITY, Calif., March 09, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (RVMD), a clinical-stage oncology company...
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) — Retrophin Inc. (NASDAQ: RTRX) today announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety and efficacy of sparsentan in focal segmental glomerulosclerosis...
FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced receipt of approval from the Ethics Committee of the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in...
Email
Text